Histogenics Corp (HSGX) Releases Earnings Results, Misses Expectations By $-0.01 EPS

Histogenics Corp (HSGX) reported quarterly earnings results on Thursday, May-12-2016. The company reported $-0.60 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $-0.59. During the same quarter in the previous year, the company posted $-0.60 EPS.

Histogenics Corp closed down -0.18 points or -11.46% at $1.39 with 64,005 shares getting traded on Tuesday. Post opening the session at $1.67, the shares hit an intraday low of $1.39 and an intraday high of $1.7399 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s lead product candidate is NeoCart. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The product has completed Phase II clinical trials and is being investigated in a Phase III clinical trial as a first-line therapy for thickness knee chondral lesions in skeletally mature adults age 18 to 55. The Company uses regenerative medicine platform to develop its products. The Company’s regenerative medicine platform is comprises bioengineering materials sciences as well as molecular and cellular biology technologies that can be utilized individually or in a variety of combinations to treat musculoskeletal-related conditions.

Histogenics Corp

Leave a Reply

Histogenics Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Histogenics Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.